Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ABVC BioPharma, Inc. (ABVC : NSDQ)
 
 • Company Description   
ABCV BIOPHARMA identifies & commercializes drugs & medical devices developed. ABCV BIOPHARMA, formerly known as AMER BRIVISION, is based in FREMONT, CA.

Number of Employees: 30

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.12 Daily Weekly Monthly
20 Day Moving Average: 43,245 shares
Shares Outstanding: 30.31 (millions)
Market Capitalization: $64.25 (millions)
Beta: 0.72
52 Week High: $6.03
52 Week Low: $1.95
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -17.19% -9.26%
12 Week -16.21% -9.08%
Year To Date -37.46% -25.63%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
44370 Old Warm Springs Blvd
-
Fremont,CA 94538
USA
ph: 510-668-0881
fax: -
None http://www.ambrivis.com
 
 • General Corporate Information   
Officers
Howard Doong - Chief Executive Officer
Eugene Jiang - Chairman of the Board of Directors
Chihliang An - Chief Financial Officer
Yen-Hsin Chou - Director
Shin-Yu Miao - Director

Peer Information
ABVC BioPharma, Inc. (CORR.)
ABVC BioPharma, Inc. (RSPI)
ABVC BioPharma, Inc. (CGXP)
ABVC BioPharma, Inc. (BGEN)
ABVC BioPharma, Inc. (GTBP)
ABVC BioPharma, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00091F106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 30.31
Most Recent Split Date: 5.00 (0.06:1)
Beta: 0.72
Market Capitalization: $64.25 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.84
Price/Cash Flow: -
Price / Sales: 141.32
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 35.48%
Sales Growth
vs. Year Ago Period: -90.11%
vs. Previous Quarter: -%
ROE
03/31/22 - -308.85
12/31/21 - -271.09
09/30/21 - -318.25
ROA
03/31/22 - -149.81
12/31/21 - -111.39
09/30/21 - -91.57
Current Ratio
03/31/22 - -
12/31/21 - 2.61
09/30/21 - 2.07
Quick Ratio
03/31/22 - -
12/31/21 - 2.60
09/30/21 - 2.05
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -2,186.90
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -2,145.77
Pre-Tax Margin
03/31/22 - -
12/31/21 - -3,149.16
09/30/21 - -2,282.14
Book Value
03/31/22 - -
12/31/21 - 0.31
09/30/21 - 0.28
Inventory Turnover
03/31/22 - -
12/31/21 - 0.24
09/30/21 - 0.28
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.01
Debt-to-Capital
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 1.35
 

Powered by Zacks Investment Research ©